Home
HelpTest Code FELBA Felbamate (Felbatol), Serum
Reporting Name
Felbamate (Felbatol), SUseful For
Determining whether a poor therapeutic response is attributable to noncompliance or lack of drug effectiveness
Monitoring changes in serum concentrations resulting from interactions with coadministered drugs such as barbiturates and phenytoin
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
SerumSpecimen Required
Supplies: Sarstedt Aliquot Tube 5 mL (T914)
Container/Tube:
Preferred: Red top
Acceptable: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions:
1. Draw blood immediately before next scheduled dose.
2. Within 2 hours of collection, centrifuge the specimen.
3. For red-top tubes, immediately aliquot serum into a plastic vial.
4. For serum-gel tubes, aliquot serum into a plastic vial within 24 hours of collection.
Specimen Minimum Volume
0.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum | Refrigerated (preferred) | 28 days | |
| Ambient | 28 days | ||
| Frozen | 28 days |
Reference Values
30.0-80.0 mcg/mL
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
80167
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| FELBA | Felbamate (Felbatol), S | 6899-9 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 80782 | Felbamate (Felbatol), S | 6899-9 |
Interpretation
Optimal response to felbamate is associated with serum concentrations of 30 mcg/mL to 80 mcg/mL.
Toxic serum concentrations for felbamate have been established at concentrations greater than 100 mcg/mL.
Clinical Reference
1. Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet. 2006;45(11):1061-1075
2. Schmidt D. Felbamate: successful development of a new compound for the treatment of epilepsy. Epilepsia. 1996;34(Suppl 7):S30-S33
3. Patsalos PN: Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239-1276
4. Rifai N, Horwath AR, Wittwer CT, eds: Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 6th ed. Elsevier; 2018
5. Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018;51(1-02):9-62
Report Available
Same day/1 to 3 daysMethod Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Day(s) Performed
Monday, Wednesday, Friday
Forms
If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:
-Neurology Specialty Testing Client Test Request (T732)
-Therapeutics Test Request (T831)